← All trials
NCT06220032
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2024
- Primary completion
- Dec 15, 2028
- Completion date
- Dec 15, 2028
- First posted
- Jan 23, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 324
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HOVON - Dutch Haemato-Oncology AssociationLead sponsor
- Free University of AmsterdamOfficial
- Utrecht UniversityCollaborator
- Utrecht UniversityOfficial
- University of AmsterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.